文献速递帕金森病与运动障碍认知障碍与痴呆

皮肤α-突触核蛋白聚集种子活性作为帕金森病新型生物标志物

Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2020-09-28

该回顾性和前瞻性诊断研究评估了尸检和活检皮肤样本,采用RT-QuIC和PMCA检测皮肤αSynP种子活性。在47例PD尸检者和43例非神经退行性对照中,RT-QuIC腹部皮肤的敏感度为94%、特异度为98%;在57例突触核蛋白病和73例非突触核蛋白病尸检者中分别为93%和93%。活体颈后和腿部皮肤活检RT-QuIC的敏感度为95%、特异度为100%。

要点

  • 皮肤αSynP种子活性可作为帕金森病及其他突触核蛋白病生前诊断的新型生物标志物。
  • RT-QuIC检测尸检腹部皮肤诊断PD的敏感度94%、特异度98%。
  • 活体皮肤活检RT-QuIC诊断PD的敏感度95%、特异度100%。

核心结论

  • 皮肤αSynP种子活性可能作为PD和其他突触核蛋白病生前诊断的新型生物标志物。

研究设计与样本

  • 共纳入57例突触核蛋白病尸检者、73例非突触核蛋白病尸检者、20例PD活体患者和21例无PD活体对照。

主要发现

  • RT-QuIC检测47例PD尸检者和43例NNCs尸检者腹部皮肤,敏感度94%(95% CI, 85-99),特异度98%(95% CI, 89-100)。
  • RT-QuIC检测57例突触核蛋白病尸检者和73例非突触核蛋白病尸检者,敏感度93%(95% CI, 85-97),特异度93%(95% CI, 83-97)。
  • PMCA检测PD尸检者腹部皮肤,敏感度82%(95% CI, 76-88),特异度96%(95% CI, 85-100)。
  • 活体颈后和腿部皮肤活检RT-QuIC检测PD患者和对照,敏感度95%(95% CI, 77-100),特异度100%(95% CI, 84-100)。
  • 活体皮肤活检PMCA检测PD患者和对照,敏感度80%(95% CI, 49-96),特异度90%(95% CI, 60-100)。

临床怎么用

  • 皮肤αSynP种子活性检测有望辅助PD及其他突触核蛋白病的生前诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Deposition of the pathological α-synuclein (αSynP) in the brain is the hallmark of synucleinopathies, including Parkinson disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). Whether real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) assays can sensitively detect skin biomarkers for PD and non-PD synucleinopathies remains unknown. OBJECTIVE: To develop sensitive and specific skin biomarkers for antemortem diagnosis of PD and other synucleinopathies. DESIGN, SETTING, AND PARTICIPANTS: This retrospective and prospective diagnostic study evaluated autopsy and biopsy skin samples from neuropathologically and clinically diagnosed patients with PD and controls without PD. Autopsy skin samples were obtained at 3 medical centers from August 2016 to September 2019, and biopsy samples were collected from 3 institutions from August 2018 to November 2019. Based on neuropathological and clinical diagnoses, 57 cadavers with synucleinopathies and 73 cadavers with nonsynucleinopathies as well as 20 living patients with PD and 21 living controls without PD were included. Specifically, cadavers and participants had PD, LBD, MSA, Alzheimer disease, progressive supranuclear palsy, or corticobasal degeneration or were nonneurodegenerative controls (NNCs). A total of 8 approached biopsy participants either refused to participate in or were excluded from this study due to uncertain clinical diagnosis. Data were analyzed from September 2019 to April 2020. MAIN OUTCOMES AND MEASURES: Skin αSynP seeding activity was analyzed by RT-QuIC and PMCA assays. RESULTS: A total of 160 autopsied skin specimens from 140 cadavers (85 male cadavers [60.7%]; mean [SD] age at death, 76.8 [10.1] years) and 41 antemortem skin biopsies (27 male participants [66%]; mean [SD] age at time of biopsy, 65.3 [9.2] years) were analyzed. RT-QuIC analysis of αSynP seeding activity in autopsy abdominal skin samples from 47 PD cadavers and 43 NNCs revealed 94% sensitivity (95% CI, 85-99) and 98% specificity (95% CI, 89-100). As groups, RT-QuIC also yielded 93% sensitivity (95% CI, 85-97) and 93% specificity (95% CI, 83-97) among 57 cadavers with synucleinopathies (PD, LBD, and MSA) and 73 cadavers without synucleinopathies (Alzheimer disease, progressive supranuclear palsy, corticobasal degeneration, and NNCs). PMCA showed 82% sensitivity (95% CI, 76-88) and 96% specificity (95% CI, 85-100) with autopsy abdominal skin samples from PD cadavers. From posterior cervical and leg skin biopsy tissues from patients with PD and controls without PD, the sensitivity and specificity were 95% (95% CI, 77-100) and 100% (95% CI, 84-100), respectively, for RT-QuIC and 80% (95% CI, 49-96) and 90% (95% CI, 60-100) for PMCA. CONCLUSIONS AND RELEVANCE: This study provides proof-of-concept that skin αSynP seeding activity may serve as a novel biomarker for antemortem diagnoses of PD and other synucleinopathies.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Becker K, Donadio V, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2020. PMID: 32986090. doi:10.1001/jamaneurol.2020.3311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。